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Abnormal metabolism of the tau protein is central to the pathogenesis of a number of dementias, including
Alzheimer’s disease. Aberrant alternative splicing of exon 10 in the tau pre-mRNA resulting in an imbalance of
tau isoforms is one of the molecular causes of the inherited tauopathy, FTDP-17. We showed previously in
heterologous systems that exon 10 inclusion in tau mRNA could be modulated by spliceosome-mediated
RNA trans-splicing (SMaRT). Here, we evaluated the potential of trans-splicing RNA reprogramming to cor-
rect tau mis-splicing in differentiated neurons in a mouse model of tau mis-splicing, the htau transgenic
mouse line, expressing the human MAPT gene in a null mouse Mapt background.Trans-splicing molecules
designed to increase exon 10 inclusion were delivered to neurons using lentiviral vectors. We demonstrate
reprogramming of tau transcripts at the RNA level after transduction of cultured neurons or after direct de-
livery and long-term expression of viral vectors into the brain of htau mice in vivo. Tau RNA trans-splicing
resulted in an increase in exon 10 inclusion in the mature tau mRNA. Importantly, we also show that the
trans-spliced product is translated into a full-length chimeric tau protein. These results validate the potential
of SMaRT to correct tau mis-splicing and provide a framework for its therapeutic application to neurodegen-
erative conditions linked to aberrant RNA processing.
INTRODUCTION
Tau is a microtubule-associated protein that accumulates in
characteristic filamentous inclusions in affected neurons in
several related neurodegenerative diseases collectively termed
tauopathies (1). Tauopathies include Alzheimer’s disease (AD),
a subgroup of frontotemporal lobar degeneration (FTLD-tau)
and the inherited tauopathy, frontotemporal dementia with
parkinsonism linked to chromosome 17 (FTDP-17), caused
by dominant mutations in the MAPT gene, encoding tau.
Tau regulates microtubule dynamics as well as a number of
microtubule-dependent properties such as axonal transport,
and might also have signaling functions (2). Six tau isoforms
are expressed in the human brain by alternative splicing of
exons 2, 3 and 10 in the tau pre-mRNA [reviewed in 3]. Of
particular significance, exon 10 (E10) encodes the second of
four microtubule-binding repeated motifs in the C-terminal
part of the protein. Thus, exclusion or inclusion of E10
gives rise to tau isoforms with three (3R tau, E102) or four
(4R tau, E10+) microtubule-binding domains. 3R Tau and
4R tau are expressed in approximately equal amounts in the
normal adult human brain, but only 3R tau is expressed
during early development.
E10 splicing has an important significance in the pathogen-
esis of tauopathies as a number of FTDP-17 MAPT mutations
affect cis-acting elements regulating E10 alternative splicing.
FTDP-17 mutations in splicing regulatory elements result in
a 2- to 3-fold increase in E10 inclusion and thus in an
excess of 4R tau (4–6). Elevated levels of 4R tau have been
reported in sporadic AD and the MAPT H1 haplotype, a risk
factor for AD, promotes E10 inclusion in tau mRNA (7).
Therefore, aberrant E10 splicing is not only causative of
disease in FTDP-17, but might be also a contributing factor
to AD.
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Tau is a major target for therapeutic intervention in tauopa-
thies but no effective treatment has been developed to date (8).
In the specific case of FTDP-17 caused by tau mis-splicing,
correction of isoform imbalance by direct intervention at the
RNA level offers several advantages over conventional therap-
ies (9). Not only does RNA therapy avoids side effects of
drugs, but, most importantly, the repaired product is under en-
dogenous transcriptional control and has the same expression
pattern as the normal transcript. A powerful and versatile
method to reprogram RNA is spliceosome-mediated RNA
trans-splicing (SMaRT) (10, 11). SMaRT creates a hybrid
mRNA by a trans-splicing reaction between the 5′ splice
site of a target pre-mRNA and the 3′ splice site of a separate
pre-trans-splicing RNA molecule (PTM). We showed previ-
ously in heterologous systems that tau E10 could be included
or excluded by trans-splicing reprogramming of tau transcripts
(12, 13). While this validated tau RNA as a target for trans-
splicing reprogramming, development of SMaRT into thera-
peutic applications requires that RNA reprogramming is
obtained with endogenous tau transcripts in differentiated
neurons and that the trans-spliced product is translated into
a chimeric protein. A suitable animal model of tau mis-
splicing to evaluate SMaRT in neurons is the htau mouse.
Htau mice are a transgenic line that expresses the entire
human wild-type human MAPT gene from a PAC transgene
in a mouse Mapt null background (14). In these animals,
human tau is in a genomic context and both 4R and 3R tau iso-
forms are expressed in adult animals, with an excess of 3R tau
over 4R tau (14, 15). Thus, compared with either adult human
neurons, expressing both isoforms in an equimolar ratio, or
wild-type adult mouse neurons, expressing 4R tau only, htau
mice have an abnormal pattern of tau splicing.
Here, we show that the 4R/3R tau isoform ratio can be
increased in neurons from htau mice in culture and in vivo
by RNA trans-splicing after lentivirus-mediated delivery of
tau-targeted PTMs. Furthermore, we show that the trans-
spliced product is translated into a full-length tau protein.
The demonstration of tau trans-splicing in post-mitotic
neurons provides a platform to explore further the therapeutic
potential of trans-splicing reprogramming for neurological
disorders.
RESULTS
Design of a lentiviral vector for delivery of tau-targeted
PTMs
For efficient transduction and long-term expression of tau-
targeted PTMs into differentiated neurons, we generated a len-
tiviral vector (LV) capable of delivering and integrating tau
PTMs into the host genome (Fig. 1A). We used a self-
inactivating LV carrying a PTM expression cassette and a
DsRed reporter gene under the control of the human ubiquitin
promoter. We previously generated two tau-targeted PTMs:
TauPTM6 and TauPTM9 designed to introduce or exclude
E10, respectively, in the mature trans-spliced tau mRNA
(12, 13). TauPTM6 was selected for LV construction in
order to reverse the excess of tau isoforms lacking E10 (i.e.
3R tau) in htau mouse brain. The trans-splicing domain of
TauPTM6 comprises a 125 nt binding domain complementary
to the 3′ end of tau intron 9, a branch point and the 3′AG splice
acceptor site. The coding sequence of the PTM consists of tau
exons 10 to 13, followed by the FLAG epitope sequence, to
monitor trans-splicing at the RNA and protein levels. The
bovine growth hormone polyadenylation signal was included
at the 3′ end of the PTM. The PTM sequence was cloned
under the CMV promoter and the resulting expression cassette
was cloned in the 3′-5′ orientation in the LV backbone (Fig. 1A).
The LV was designated as LV-TauPTM6. The transduction
efficiency of LV-TauPTM6 was assessed by transducing cul-
tured mouse cortical neurons and monitoring DsRed expres-
sion and was estimated to be 70–80% (Fig. 1B). Once
integrated into the host genome LV-TauPTM6 drives the ex-
pression of TauPTM6 RNA that is designed to hybridize
with endogenous tau pre-mRNA to produce a trans-spliced
product containing PTM-encoded exons 10 to 13 and the
FLAG sequence at the 3′ end (Fig. 1C). Tau pre-mRNA
molecules not involved in a trans-splicing event would be
cis-spliced to produce tau mRNA either including or
excluding E10.
The potential of lentivirus-delivered TauPTM6 to promote
trans-splicing at the level of E10 was assessed in HeLa cells
first transduced with LV-TauPTM6 and then transfected with
the TauEx9-11WT minigene consisting of MAPT exons 9, 10
and 11 and minimal intronic sequences flanking E10 (16).
An 866 bp trans-spliced product containing minigene-derived
exon 9 and TauPTM6-derived exons 10–13 and FLAG
epitope sequences was detected by RT–PCR using a
minigene-specific forward primer and the PTM-specific
reverse primer, FLAGR, complementary to the FLAG se-
quence (Fig. 2, top panel). Although TauEx9-11WT produces
mainly 4R tau RNA, RT–PCR detection of both cis- and
trans-spliced products showed a multiplicity of infection
(m.o.i.)-dependent increase in E10 inclusion in the mature
RNA (Fig. 2, bottom panel).
Trans-splicing reprogramming of endogenous tau
RNA after lentivirus-mediated PTM delivery
To determine if trans-splicing with an endogenous tau
pre-mRNA target could be achieved through LV-TauPTM6
transduction, we used human neuroblastoma SH-SY5Y cells.
SH-SY5Y cells were transduced with LV-TauPTM6 at differ-
ent m.o.i. or with a control LV. RNA was extracted 1 week
after transduction and analyzed by RT–PCR using a forward
primer, 9F, complementary to an exon 9 sequence, and the
PTM-specific reverse primer, FLAGR, to detect trans-spliced
products. A 580 bp product corresponding to the size expected
for a trans-spliced product was detected (Fig. 3A, top panel).
Due to their fetal characteristics, proliferating SH-SY5Y cells
mainly express 3R tau isoforms (17). Amplification of reverse-
transcribed RNA using the 9F forward primer and a reverse
primer, 13R, complementary to an exon 13 sequence, a com-
bination that detects both cis- and trans-spliced products,
showed an increase in 4R tau mRNA (Fig. 3A, middle
panel). Both the level of the trans-spliced product and the in-
crease in 4R tau RNA were m.o.i.-dependent, being particular-
ly evident at the highest viral vector concentration (m.o.i. ¼
10). The 4R/3R ratio was lower than 0.1 in control cells but
raised to 0.5 in cells transduced with LV-TauPTM6 at
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m.o.i. ¼ 10 (Fig. 3B). The increase in the isoform ratio corre-
sponds to a percentage of isoform conversion of 32% at
m.o.i. ¼ 10. The increase in the 4R/3R ratio was due to a con-
comitant increase in 4R tau RNA and a decrease in 3R tau
RNA (Fig. 3C).
Correction of tau mis-splicing in htau mouse neurons
in culture
To evaluate tau trans-splicing reprogramming in differentiated
neurons, primary neurons from htau mice were transduced
with LV-TauPTM6. Htau mice are a transgenic line that
expresses the human wild-type human MAPT gene from a
human PAC transgene in a mouse Mapt null background (14).
Primary neurons from htau mice were transduced at 3 days in
vitro (DIV3) at various viral vector m.o.i. and analyzed
between 7 and 10 days after transduction. The number of viral
particles integrated per neuron was estimated by qPCR analysis
of DNA extracted from transduced neurons. The values obtained
were consistent with the m.o.i. calculated from viral titers.
RNA extracted from transduced neurons was analyzed by
RT–PCR using primers hybridizing in exon 9 and in the
FLAG sequence (9F and FLAGR), as above. As in
SH-SY5Y cells, a 580 bp trans-spliced product was generated
from RNA from neurons transduced at m.o.i. ¼ 5 and 10
(Fig. 4A, top panel). Transduction with lower amounts of
LV-TauPTM6 (m.o.i. ¼ 2) failed to produce detectable
amounts of trans-spliced RNA. Sequencing of the 580 bp
RT–PCR product confirmed that a correct exon 9–exon 10
junction had been created and that the full tau exon 10 to
exon 13 sequence encoded by TauPTM6 as well as the
FLAG sequence at the 3′ end was incorporated into the trans-
spliced product (Fig. 4B). 3R and 4R tau isoforms in trans-
duced htau neurons were detected by RT–PCR with primers
hybridizing in exons 9 and 13 (9F–13R), as above. Htau
neurons at early stages of culture express only 3R tau; trans-
splicing of tau RNA was accompanied by the production
and m.o.i.-dependent increase of 4R tau mRNA (Fig. 4A,
middle panel). The 4R/3R ratio raised from 0.1 in control
neurons to 0.4 and 0.6 in neurons transduced with
LV-TauPTM6 at m.o.i. ¼ 5 and 10, respectively (Fig. 4C).
The change in the ratio corresponds to a percentage of
isoform conversion of 36% at m.o.i. ¼ 10. As for
SH-SY5Y cells, the increase in the 4R/3R ratio was due to
an increase in 4R tau RNA accompanied by a decrease in
3R tau RNA, the latter being clearly apparent at m.o.i. ¼ 10
(Fig. 4D).
Translation of trans-spliced tau RNA into a chimeric
protein
We next analyzed whether the trans-spliced product detected
at the RNA level was translated into a bona fide chimeric
tau protein. SH-SY5Y cells and primary neurons from htau
Figure 1. Trans-splicing strategy for lentiviral delivery of TauPTM6. (A) Map of the LV designed for simultaneous delivery of TauPTM6 and DsRed. The viral
backbone comprises: LTR, long-terminal repeat; w, HIV encapsidation sequence; cPPT, central polypurine tract; CTS, central termination sequence; 3′PPT,
3′polypurine tract; DU3, deletion of the U3 portion of 3′LTR. The DsRed reporter cassette consists of DsRed under the human ubiquitin promoter (in the
5′ –3′ direction) followed by the WPRE sequence. In the 3′ –5′ direction, under the CMV promoter, the TauPTM6 sequence consists of a trans-splicing
domain (TSD) comprising a 125 nt binding domain (BD) complementary to the 3′ end of tau intron 9, a branch point (BP) and the 3′AG splice acceptor site
followed by tau exons 10–13, the FLAG epitope sequence (F) and the bovine growth hormone (BGH) polyadenylation signal. (B) DsRed expression in
mouse cortical neurons transduced with LV-TauPTM6. Scale bar: 100 mm. (C) RT–PCR strategy to detect cis- and trans-splicing products. Schematic repre-
sentation of cis- and trans-splicing events from tau pre-RNA (left) and the corresponding mRNA products (right). Arrows indicate the position of forward (9F) or
reverse (13R, FLAGR) PCR primers. The expected size of PCR products is indicated for each splicing product.
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mice were transduced with LV-TauPTM6 at different m.o.i.
and 10 days later FLAG-tagged proteins were immunoprecipi-
tated using an immobilized FLAG antibody (Fig. 5A). Immu-
noprecipitation products were analyzed by western blotting
using an antibody to N-terminal amino acids 1–16 of human
tau. Both in SH-SY5Y cells (Fig. 5B) and in htau neurons
(Fig. 5C), a protein of 50 kDa, co-migrating with tau from
whole cell lysates (input samples), was detected in cells trans-
duced with LV-TauPTM6 at m.o.i. ¼ 5 and 10 and not in cells
transduced with a control LV. This demonstrates the transla-
tion of the trans-spliced product into a full-length tau
protein, with an intact N-terminus and the FLAG epitope at
the C-terminus. Similarly to the trans-spliced RNA, the
amount of FLAG-immunoprecipitated tau increased with in-
creasing m.o.i. (Fig. 5B and C).
The N-terminal tau antibody detects only trans-splicing oc-
curring with tau RNA. Immunoprecipitates from transduced
htau neurons were also probed with an antibody to the C-
terminus of tau, raised against amino acids 243–441 of
human tau, a sequence encoded by TauPTM6. TauPTM6
includes the entire C-terminus of tau, from exons 10 to exon
13, as well as the FLAG epitope sequence. Thus, trans-
splicing of TauPTM6 on targets other than tau would result
in chimeric proteins containing the C-terminus of tau, detected
by the C-terminal tau antibody used, as well as the FLAG
epitope sequence. The C-terminal tau antibody detected a
single 50 kDa band in FLAG immunoprecipitates,
co-migrating with tau from whole cell lysates (Fig. 5D).
Detection of a single band with the C-terminal tau antibody
in FLAG-immunoprecipitated proteins indicates that trans-
lated potential off-target trans-spliced products are minimal.
Untranslated off-target products would be apparent at the
RNA level only and would require methods such as rapid amp-
lification of complementary DNA ends (RACE) to be detected.
Two out of three off-target trans-spliced products will be out
of frame and degraded by nonsense-mediated decay; only off-
target products that are translated could represent a problem.
Detection of a single band with a C-terminal tau antibody
also rules out the possibility of direct translation from the
PTM, which would have produced a smaller product immu-
noreactive for the tau C-terminus.
Correction of tau mis-splicing in vivo in adult
htau mouse brain
Although tau trans-splicing can be obtained in cultured
neurons from htau mice after lentivirus-mediated PTM deliv-
ery, culture conditions only partly reproduce in vivo conditions
compatible with therapeutic applications. Therefore, we next
conducted a small-scale pilot study in adult htau mice. For
PTM delivery to the brain, we constructed second generation
LVs, based on the original LV-TauPTM6 design. The CMV
promoter was replaced by either the synapsin promoter for
enhanced and neuron-specific expression or by the ubiquitin
promoter. The bovine growth hormone polyadenylation
signal was replaced by the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) for increased
RNA stability. The DsRed reporter cassette was omitted to
avoid promoter competition. The new LVs were designated
as LVSyn-TauPTM6 and LVUb-TauPTM6, respectively
(Fig. 6A).
LVSyn-TauPTM6, LVUb-TauPTM6 or an LV expressing a
PTM lacking the trans-splicing domain (PTMDTSD) were
stereotaxically injected into the prefrontal cortex of 12–14
week-old htau mice. Trans-splicing was evaluated 8 months
after injection by RT-PCR using the FLAGR reverse primer
and the forward primer, 9.1F, that hybridizes with exon 9 as
well as with exon 11, included in the PTM coding sequence,
in order to detect PTM expression as well as trans-splicing
(12). In addition to a 360 bp product, demonstrating PTM ex-
pression, a 550 bp trans-spliced product was detected after in-
jection with LVSyn-TauPTM6 or LVUb-TauPTM6 (Fig. 6B).
Sequencing of the 550 bp product confirmed that a correct
exon 9–exon 10 junction had been generated. This demon-
strates that trans-splicing has occurred in vivo between en-
dogenous tau RNA and TauPTM6. Unlike embryonic
neurons cultured from htau mice, that express only 3R tau
(Fig. 4A), adult htau mice express all human tau isoforms,
with an excess of 3R tau over 4R tau [(14, 15) and Fig. 6C].
Amplification of reverse-transcribed RNA using the 9F-13R
primer combination, detecting both isoforms, demonstrated
an increase in 4R tau mRNA concomitant with a decrease in
3R tau after injection with LVSyn-TauPTM6 (Fig. 6C). FLAG-
Figure 2. Trans-splicing modulation of E10 inclusion in tau transcripts. HeLa cells were transduced with LV-TauPTM6 and 2 to 3 days later were transfected
with the TauEx9-11 minigene consisting of tau exons 9-10-11 and 498 bp 5′ and 264 bp 3′ of intronic sequences flanking E10. HeLa cells co-transfected with
TauEx9-11 and TauPTM6 in pcDNA3 were used as a positive control. RT–PCR analysis with the forward primer VctF, specific for the target minigene and the
PTM-specific reverse primer FLAGR, complementary to the FLAG epitope sequence, demonstrate trans-splicing between minigene transcripts and TauPTM6
(top panel). Both cis- and trans-spliced products were detected by RT–PCR with the forward primer VctF and the reverse primer 11R, corresponding to an exon
11 sequence; transduction with LV-TauPTM6 resulted in an increase in E10 inclusion (bottom panel).
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tagged proteins were immunoprecipitated from brain extracts
and immunoprecipitation products were analyzed by western
blotting using N- or C-terminal tau antibodies, as above. An
increased signal was detected with both antibodies after injec-
tion with LVSyn-TauPTM6 (Fig. 6D). Thus, the tau trans-
spliced product is translated into a full-length tau protein,
with an intact N-terminus and the FLAG epitope at the C-
terminus.
DISCUSSION
Tau mis-splicing is one of the molecular causes of inherited
tauopathies. Using RNA trans-splicing in htau mice with a
lentiviral delivery system to achieve long-term expression of
trans-splicing molecules, we have demonstrated efficient cor-
rection of endogenous tau mis-splicing in neurons in vitro and
in vivo in the brain of adult mice. Importantly, the trans-
spliced RNA is translated into a full-length chimeric tau
protein. Therefore, our results highlight the therapeutic poten-
tial of SMaRT to correct tau mis-splicing.
Another example of successful use of trans-splicing in
neurons in vivo is SMN exon 7 inclusion in the SMN2
transcript in a mouse model of spinal muscular atrophy
(SMA) (18–20). In this paradigm, production of a functional
SMN protein after trans-splicing has been inferred through
changes in total SMN protein (18–20), but not demonstrated
directly. Successful translation of a chimeric protein after
trans-splicing of endogenous transcripts has been reported
for keratin 14, mutated in epidermolysis bullosa (21). Achiev-
ing trans-splicing in the brain necessitates an appropriate PTM
delivery system. In the SMA example mentioned above, PTMs
were delivered by intraventricular injection of plasmid DNA
in neonatal animals. While this is suitable for experimental
purposes in animals, this delivery method is not directly ap-
plicable in a therapeutic context. Intraventricular injection in
human subjects or adult animals is effective for proteins and
oligonucleotides, but not suitable for plasmids and has a
number of other limitations as highlighted by Butchbach
(22). On the other hand, we have shown that tau reprogram-
ming could be achieved in vivo in adult animals by direct
stereotaxic injection and long-term expression of a viral
vector into the brain parenchyma, a delivery strategy compat-
ible with therapeutic applications.
Htau mice represent an excellent in vivo system in which to
evaluate strategies to correct tau mis-splicing. Htau mice
Figure 3. Trans-splicing reprogramming of endogenous tau RNA in SH-SY5Y cells after lentivirus-mediated PTM delivery. Human neuroblastoma SH-SY5Y
cells were transduced with LV-TauPTM6 at the indicated m.o.i., or with a control LV at m.o.i. ¼ 10. Total RNA was extracted 7 days after transduction and
reverse-transcribed. (A) PCR analysis of reverse-transcribed RNA from transduced cells. Top panel: PCR analysis with 9F-FLAGR primers detects a product of
580 bp only in cells transduced with LV-TauPTM6. Middle panel: 3R and 4R tau isoforms were detected with primers 9F and 13R. An increase in 4R tau RNA
was observed in LV-TauPTM6-transduced cells. GAPDH mRNA was used for normalization (bottom panel). No RT: PCR with no RT using RNA from cells
transduced with LV-TauPTM6 at m.o.i. ¼ 10. (B) Quantitative analysis of 4R/3R tau RNA ratio. The 4R/3R ratios are expressed as mean+SEM (∗P, 0.05,
∗∗P, 0.01, n ¼ 3). The percentage of isoform conversion is indicated above the respective bars. (C) Individual values of 4R and 3R tau RNA content for each
condition. Values are expressed in arbitrary units as mean+SEM (∗P , 0.05, ∗∗P , 0.025, n ¼ 3).
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develop a tau pathology with tau hyperphosphorylation and ag-
gregation as well as extensive neuronal death during aging (14,
15). Htau mice express human tau at about four times the level
of endogenous mouse tau and the tau pathology observed in
these animals is likely due to a combination of tau overexpres-
sion and expression of both 3R and 4R tau (as opposed to the
expression of 4R tau only in wild-type adult mice). Expression
of 3R tau in adult mice is unlikely to be sufficient to induce tau
pathology in htau mice. Indeed, other transgenic mice expres-
sing the entire human MAPT gene in a Mapt2/2 background
have been described (23). These animals have a similar
pattern of tau isoform expression as htau mice, but the
overall level of tau is lower than in htau mice, and they do
not develop a tau pathology (23). To date, there has been no
animal model reproducing the pathological phenotype
caused by splicing defects occurring in FTDP-17, in which
the effect of splicing modulation can be evaluated.
For therapeutic applications, trans-splicing can elicit either
increase or reduction of E10 inclusion from wild-type tau tran-
scripts as well as from transcripts containing FTDP-17 muta-
tions affecting E10 splicing (13). Trans-splicing modulation
of E10 splicing is independent of the specific mutation affect-
ing splicing and can therefore have a general application for
the correction of the downstream consequences of mutations
affecting splicing regulatory elements. Other methods of tau
mis-splicing correction include the use of antisense oligonu-
cleotides blocking splice junctions. Although antisense oligo-
nucleotides would represent a more direct approach than
trans-splicing and are promising for the treatment of brain dis-
eases (24, 25), they require, in most cases, sustained delivery
by intraventricular infusion. Modulation of tau splicing using
antisense oligonucleotides has been obtained in vitro using
minigenes or neuronal cell lines (26–28); however, there has
been no report to date of their use in vivo.
In summary, the demonstration of successful in vivo trans-
splicing correction of tau mis-splicing in adult brain provides a
framework to be evaluated further for its therapeutic applica-
tion for tauopathies and other neurological disorders, especial-
ly for neurodegenerative conditions caused by abnormal RNA
processing (29, 30), including abnormal activity of RNA-
binding proteins (31).
MATERIALS AND METHODS
Lentiviral vectors
The lentiviral backbone used is derived from the original
pTrip vector (32) with several modifications, as described pre-
viously (33). To produce LVs expressing TauPTM6, the
TauPTM6 cassette, including the CMV promoter and the
BGH polyadenylation sequence (pA), was amplified from
the TauPTM6 construct in pcDNA3.1 (designed and produced
by VIRxSYS Corporation, Gaithersburg, MD, USA) described
previously (12) and subcloned into the viral backbone vector.
Details of cloning, lentivirus production and transduction of
cell lines are described under Supplementary data.
Animals
Htau transgenic mice, in a C57BL/6 background, were
obtained from Jackson Laboratories (Bar Harbour, Maine,
USA; B6.Cg-Mapttm1 (EGFP) Klt Tg(MAPT)8cPdav/J.
Stock number: 005 491). Mice were genotyped by PCR to
confirm the presence of the human MAPT transgene and the
Figure 4. Correction of tau mis-splicing in cultured cortical neurons from htau mouse after lentivirus-mediated PTM delivery. Cultured cortical neurons from
htau mice were transduced at DIV3 with LV-TauPTM6 at the indicated m.o.i., or with a control LV at m.o.i. ¼ 10. Total RNA was extracted 7 days after trans-
duction and reverse-transcribed. (A) PCR analysis of reverse-transcribed RNA from transduced neurons. Top panel: a 580 bp PCR product was detected with
9F-FLAGR primers only in neurons transduced with LV-TauPTM6 at m.o.i. ¼ 5 and 10. Middle panel: 3R and 4R tau isoforms were detected with primers 9F
and 13R. GAPDH mRNA was used for normalization (bottom panel). No RT: PCR with no RT using RNA from cells transduced with LV-TauPTM6 at m.o.i. ¼
10. (B) Details of the sequence of the 9F-FLAGR PCR product showing a correct splice junction between exons 9 and 10 and the presence of the FLAG epitope
sequence at the 3′ end of the trans-spliced product. (C) Quantitative analysis of 4R/3R tau RNA ratios. 4R/3R ratios are expressed as mean+SEM (∗∗P , 0.01,
n ¼ 3). The percentage of isoform conversion is indicated above the respective bars. (D) Individual values of 4R and 3R tau RNA content. Values are expressed
in arbitrary units as mean+SEM (∗P , 0.05, ∗∗P , 0.025, n ¼ 2).
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mouse Mapt null background using the primers listed in Sup-
plementary data. All animal procedures were conducted in ac-
cordance with the UK Home Office, Animals Scientific
Procedures Act 1986.
Primary neuronal cultures and viral transduction
Cortical neurons were obtained from embryonic day 16 (E16)
mouse embryos and dissociated with the papain dissociation
system (Worthington Biochemical Corp., NJ, USA) following
the manufacturer’s instructions. Cells were plated onto 6-well
plates coated with poly-D-lysine (10 mg/ml) at a density of
106 cells per well and cultured in Neurobasal medium (Invitro-
gen) supplemented with a 2% (v/v) B-27 serum-free supple-
ment, 0.5 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin. Cells were incubated at 378C in a 5%
CO2/95% air atmosphere. For fluorescence microscopy, the
cells were plated onto poly-D-lysine-coated glass coverslips
in 12-well plates at a density of 2 × 105 cells per well and cul-
tured under the same conditions. Viral transductions were per-
formed at 3 days in vitro (DIV3), at an m.o.i. of 2, 5 or 10 by
adding 5–30 ml of concentrated viral suspension (in phosphate
buffered saline, PBS) in a final volume of 1 ml of Neurobasal
medium per well. Twenty-four hours after transduction, the
medium was replaced with fresh medium and the cells were
cultured for 7–10 further days before RNA or protein extrac-
tion. To detect DsRed fluorescence, transduced neurons were
fixed in 4% (w/v) paraformaldehyde for 10 min, then rinsed
three times in PBS, with the last wash containing DAPI and
mounted in DakoCytomation fluorescent mounting medium.
Slides were viewed under a Zeiss Axioskop fluorescence
microscope with the appropriate filter sets and imaged using
Metamorph software. The number of viral particles integrated
into the host genome was estimated by qPCR using DNA from
transduced neurons. Quantification was performed with SYBR
Green with two separate sets of primers, to detect either the
LTR or the WPRE sequence.
Stereotaxic injections
Mice aged 12–14 weeks (weight 25–30g) were anesthetized
using ketamine-HCl (100 mg/kg; Ketaset) and xylazine-HCl
(10 mg/kg, Rompun 2%, Bayer), i.p. 2 ml of viral suspension
(0.5–1 × 106 TU) were stereotaxically injected into the
brain at the following coordinates (34): anteroposterior:
+2.5 mm, lateral: +0.5 mm, dorso-ventral: 22.0 mm, mea-
sured from the Bregma, at an injection rate of 0.2 ml/min.
After surgery, the skin was sutured and the animals kept at
378C until complete recovery. Carprofen (5 mg/kg, s.c.) was
administered immediately after surgery and 24 h later. Mice
were sacrificed by cervical dislocation 8 months after injec-
tion, the brain dissected and 1 mm3 of tissue around the
injected area was dissected, snap frozen and stored at
2808C until RNA or protein extraction.
RT–PCR analysis of cis- and trans-splicing
Total RNA and DNA were isolated from transduced cells
using the AllPrep DNA/RNA Mini kit (Qiagen). RNA from
LV-injected brains was extracted using a RNeasy Lipid
Tissue kit (Qiagen). Reverse transcription was performed
using a TaqMan RT kit (Applied Biosystems) with oligo(dT)
or an equimolar ratio of oligo(dT) and random hexamers. To
detect cis- and trans-splicing products, reverse-transcribed
RNA was amplified by PCR using Go Taq polymerase
Figure 5. Translation of trans-spliced RNA into a chimeric protein. (A) Diagram of the strategy used for the detection of chimeric proteins by immunoprecipita-
tion. An immobilized mouse monoclonal FLAG antibody was used to immunoprecipitate chimeric proteins. Immunoprecipitated proteins were analyzed by
western blotting with N-terminal or C-terminal tau antibodies. The N-terminal part of the protein (grey box) corresponds to the part encoded by endogenous
RNA (exons 1–9) and the C-terminal part (white box) corresponds to the part encoded by the PTM (exons 10–13 and FLAG epitope). (B–D) Immunoprecipita-
tion analysis of FLAG-containing proteins from transduced cells. SH-SY5Y cells (B) or cortical neurons from htau mice at DIV3 (C and D) were transduced with
LV-TauPTM6 at the indicated m.o.i. or with a control lentivirus (m.o.i. ¼ 10). Transduced cells were lysed 14–16 days later and proteins immunoprecipitated
with a FLAG antibody were analyzed by western blotting with an N-terminal tau antibody, a GAPDH antibody (B and C) or a C-terminal tau antibody (D) (input:
5 ml of cell lysate before immunoprecipitation). All samples had similar levels of tau before immunoprecipitation. No GAPDH immunoreactivity was detected in
immunoprecipitates, ruling out non-specific precipitation by the FLAG antibody or by the affinity gel.
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(Promega) using conditions and primers detailed in Supple-
mentary data.
Immunoprecipitation and western blotting
Ten days after transduction, the cells were washed in PBS at
48C and lysed in lysis buffer [50 mM Tris–HCl, pH 7.4;
150 mM NaCl; 1 mM EDTA; 1% (v/v) Triton X-100] contain-
ing a protease inhibitor cocktail (Complete Mini, Roche).
Brain samples were homogenized in lysis buffer. FLAG-
tagged proteins were immunoprecipitated using EZ-view anti-
FLAG M2 Affinity gel (Sigma). Immunoprecipitates were
analyzed by western blotting using antibodies to the N- or
C-terminus of tau.
Additional details of reagents and protocols are described in
Supplementary data.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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